Mitsubishi Tanabe Pharma America, Inc. (MTPA) has entered a collaboration with the Massachusetts General Hospital (MGH) Neurological Clinical Research Institute (NCRI) to conduct a study designed to identify and measure specific biomarkers in people with amyotrophic lateral sclerosis (ALS).  “We are honored to be working with the team at MGH on our first clinical trial in the U.S.,” said Stephen Apple, M.D., senior medical director, Medical Affairs, MTPA. “This biomarker tri...